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Objectives. This randomized clinical trial tested whether fish oil 
supplements can improve human coronary atherosclerosis. 
Background. Epidemiologic studies of populations whose in- 
take of oily fish is high, as well as laboratory studies of the effects 
of the polyunsaturated fatty acids in fish oil, support the hypoth- 
esis that fish oil is antiatherogenic. 
Methods. Patients with angiographically documented coronary 
heart disease and normal plasma lipid levels were randomized to 
receive either fish oil capsules (n = 31), containing 6 g of n-3 fatty 
acids, or olive oil capsules (n = 28) for an average duration of 28 
months. Coronary atherosclerosis on angiography was quantified 
by computer-assisted image analysis. 
Results. Mean (-+SD) baseline characteristics were age 62 -+ 7 
years, plasma total cholesterol concentration 187 -+ 31 mg/dl 
(4.83 -+ 0.80 mmol/liter) and triglyceride levels 132 -+ 70 mg/dl 
(1.51 + 0.80 mmol/liter). Fish oil lowered triglyceride levels by 
30% (p = 0.007) but had no significant effects on other plasma 
lipoprotein levels. At the end of the trial, eicosapentaenoic a id in 
adipose tissue samples was 0.91% in the fish oil group compared 
with 0.20% in the control group (p < 0.0001). At baseline, the 
minimal lumen diameter of coronary artery lesions (n = 305) was 
1.64 - 0.76 ram, and percent narrowing was 48 -+ 14%. Mean 
minimal diameter of atherosclerotic oronary arteries decreased 
by 0.104 and 0.138 mm in the fish oil and control groups, 
respectively (p = 0.6 between groups), and percent stenosis 
increased by 2.4% and 2.6%, respectively (p = 0.8). Confidence 
intervals exclude improvement by fish oil treatment of >0.17 mm, 
or >2.6%. 
Conclusions. Fish oil treatment for 2 years does not promote 
major favorable changes in the diameter of atherosclerotic coro- 
nary arteries. 
(J Am Coil Cardiol 1995;25:1492-8) 
Evidence from several lines of investigation suggests that n-3 
polyunsaturated fatty acids may protect against atherosclerotic 
vascular disease. In arctic populations, low mortality from 
coronary heart disease is attributed to a diet that is rich in oily 
fish (1). In a controlled trial in British patients with coronary 
heart disease, intake of fatty fish significantly reduced coronary 
heart disease death (2). The protective ffect of fish intake 
could be caused by the fish oil (3,4), by other nutrients in fish 
or by an indirect effect of fish intake on other aspects of the 
diet. The n-3 polyunsaturated long-chain fatty acids unique to 
fish oils demonstrate several biologic effects that could be 
antiatherogenic, ncluding arterial vasodilation (5,6), reduced 
thromboxane and enhanced prostacyclin synthesis (3,4), inhi- 
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bition of platelet aggregation (3,4), decreased blood pressure 
(7), reduction of plasma triglyceride l vels (8) and elevation of 
high density lipoprotein (HDL)2 cholesterol (9,10). However, 
other effects of n-3 fatty acids may have a proatherogenic 
effect, including elevations of plasma low density lipoprotein 
(LDL) cholesterol (9,11,12) and glucose levels (13) and en- 
hanced oxidation of LDL cholesterol (14,15). In several animal 
models of atherosclerosis, fish oil diminished atherogenesis 
(16-22), but other studies have found no effect (15,23,24) or 
even worsening (25-27). Studies of fish oil in human coronary 
atherosclerosis have been limited to attempts to prevent 
restenosis after coronary angioplasty, and results have been 
mixed (28,29). Therefore, to date, the value of n-3 fatty acids as 
agents for prevention or treatment of human atherosclerosis 
remains undetermined. In the present study, in patients with 
coronary artery disease, we tested the effect of a moderate 
dose of fish oil on atherosclerosis in native coronary arteries. 
Methods  
Patients. Eligible patients had narrowing of ->30% lumen 
diameter of a major coronary artery, as shown by diagnostic 
coronary angiography at either Brigham and Women's or Beth 
Israel Hospitals, a total cholesterol concentraation <250 mg/dl 
(6.43 mmol/liter) and triglyceride l vel <350 mg/dl (4.0 retool/ 
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liter) and were between the ages of 30 and 75 years. Patients 
were determined tobe eligible by lipid criteria from measure- 
ments on two qualifying visits conducted 1 to 2 weeks apart. 
Qualifying visits were delayed at least 8 weeks after hospital 
discharge for patients who had acute myocardial infarction and 
at least 12 weeks for patients who underwent coronary artery 
bypass urgery or angioplasty. Patients with congestive heart 
failure; liver, renal or serious gastrointestinal disease; insulin- 
dependent diabetes mellitus; current cigarette smoking; of y 
alcohol intake >14 drinks/week were excluded. Randomiza- 
tion of patients was stratified according to clinical management 
of their coronary artery disease (medical or surgical) and 
total/HDL cholesterol ratio (>6.0 or -<6.0). Forty-one of 80 
patients were randomized to the fish oil group and 39 to the 
control group. The study was approved by the Institutional 
Review Boards of Brigham and Women's and Beth Israel 
Hospitals, and written informed consent was obtained at the 
first qualifying visit and again before the follow-up coronary 
catheterization. 
During the initial hospital stay for coronary catheterization, 
dietary instruction was provided to every patient according to 
the guidelines of the National Cholesterol Education Program 
Step I (30). The instruction was reinforced, and a 7-day diet 
record was collected at the randomization visit and every 3 
months during the trial. The diet records were analyzed using 
a computerized nutrient data base (Food Processor II, ESHA 
Research). 
Protocol. Patients in the fish oil group were given bottles 
containing a 3-month supply of fish oil capsules (Promega, 
Parke-Davis). They were instructed to take twelve 1-g capsules 
daily, in divided doses, preferably after meals. Each fish oil 
capsule contained 500 mg of n-3 polyunsaturated fatty acids 
composed of eicosapentaenoic acid (240 mg), docosahexaenoic 
acid (160 mg) and other (100 mg) (mainly docosapentaenoic 
acid). Therefore, the total daily dose of n-3 fatty acids was 6 g. 
The control group was treated similarly with capsules of olive 
oil that were identical in appearance to the fish oil capsules. 
The patients and personnel responsible for laboratory mea- 
surements, cardiac atheterization, a d analysis of angiography 
films were blinded to treatment assignment. 
Every 12 weeks, a research nurse reviewed with the patients 
side effects, diet, and concomitant medications and performed 
a pill count. Every 24 weeks, the patients received an interval 
medical history and physical examination bya physician. At the 
12- and 24-week visits and every 24 weeks thereafter, a fasting 
blood sample was obtained for lipid analysis. At the end of the 
study, a sample of adipose tissue was aspirated from gluteal fat 
for fatty acid measurements. 
If the total cholesterol level of any patient increased to 
_>250 mg/dl (6.43 mmol/liter) on two consecutive measure- 
ments, intensified ietary instruction was given, followed by 
drug therapy with cholestyramine 4 to 16 g or nicotinic acid 2 g, 
or both, as needed to lower total cholesterol to <250 mg/dl 
(6.43 mmol/liter). 
Lipid measurements. Plasma lipids were measured on 
fasting fresh plasma at the Lipid Research Laboratory, 
Brigham and Women's Hospital. Cholesterol and triglyceride 
levels were measured by enzymatic reagents (Boehringer 
Mannheim) in whole plasma (31). The HDL cholesterol was 
measured in plasma after precipitation of very low density 
lipoprotein (VLDL) and LDL cholesterol by dextran and 
magnesium chloride (32). The LDL cholesterol was calculated. 
The fatty acid composition of adipose tissue was determined by 
capillary gas chromatography (33). Apolipoprotein B was 
measured by immunonephelometry (Inkstar Corp.) in one 
batch on samples continuously stored at -80°C using calibra- 
tors provided by the Centers for Disease Control. Lipoprotein 
Lp(a) was measured by sandwich enzyme-linked immunosor- 
bent assay (Terumo, Inc.). 
Cardiac catheterization. At the baseline cardiac catheter- 
ization, the following conditions were recorded and repro- 
duced at the time of the repeat procedure: cine camera ngle 
and skew, contrast agent (ionic or nonionic), sequence of 
angiographic views and the dosing of vasoactive medications. 
To confirm reproduction ofangiographic views, the initial cine 
film was viewed on a projector in the catheterization laboratory 
during the repeat procedure. On hospital admission on the day 
before the angiography, the patients were treated with the 
same cardiac medications they were taking at the time of the 
initial procedure unless contraindicated for medical reasons. 
The two catheterizations were performed at the same time of 
day whenever possible to eliminate any diurnal variation in 
vasomotor tone. 
Quantitative angiography. From films unlabeled as to 
treatment assignment, coronary artery lumen diameter was 
quantitated by an operator-interactive program as previously 
described (34). The classification of segments was similar to 
that used in other trials (35). Lesions were defined as lumen 
obstructions >20%. New lesions were defined as vessels with 
an obstruction <20% at the time of initial catheterization, 
_>20% at follow-up examination a d a change _>7.8% diameter 
stenosis, previously determined to be significant (34). For 
vessels without a lesion, segments >2.0 mm, were analyzed. 
Lesions that underwent angioplasty and adjacent vessel seg- 
ments were not analyzed. Five consecutive frames from the 
same phase of the cardiac ycle (preferably end-diastole) were 
analyzed by edge detection (36,37) after threefold to fourfold 
optical magnification and digitization into a 512 × 512-pixel 
array. The minimal diameter of a stenosis was defined as the 
minimal diameter of a polynomial fit to the five pixels sur- 
rounding the minimal point of the diameter-length relation. 
Statistics. The primary outcome variable was the change in 
minimal diameter of coronary artery lesions expressed as a 
continuous variable. The individual coronary artery lesions 
comprised the basic units in the analysis. Unbypassed and 
bypassed vessel segments were included as in a previous trial 
(38). The treatment effect was adjusted by multiple logistic 
regression for the intraclass correlation between changes in 
lesions in a person (39); the initial diameter of the lesions, 
because initial diameter has been shown to be a significant 
predictor of lesion change (40); and the differences between 
the groups in the proportion of bypassed and unbypassed 
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Table 1. Baseline Characteristics of59 Study Patients 
Fish Oil Group Control Group 
(n = 31) (n = 28) 
Age (yr) 62 + 7 62 +_ 7 
Duration in trial (days) 829 _+ 127 890 ± 123 
Duration from initial to final 958 ± 136 993 ± 96 
cardiac catheterization 
Gender (M/F) 29/2 26/2 
Hypertension 15 (48%) 10 (36%) 
Diabetes 5 (16%) 3 (11%) 
Family history of CVD 21 (68%) 13 (46%) 
CABG 16 (52%) 12 (43%) 
MI 17 (55%) 16 (57%) 
Medication 
Beta-blockers 17 (55%) 15 (54%) 
Calcium channel b ockers 16 (52%) 12 (43%) 
Nitrates 13 (42%) 7 (25%) 
Antiplatelet agents 30 (97%) 26 (93%) 
ACE inhibitors 3 (10%) 3 (11%) 
Oral hypoglycemic drugs 5 (16%) 1 (4%) 
Data presented are mean value ± SD or number (%) of patients. ACE = 
angiotensin-converting enzyme; CABG = coronary artery bypass graft surgery; 
CVD - cardiovascular disease; F = female; M = male; MI = myocardial 
infarction. 
lesions. The effects of covariates, uch as age, baseline plasma 
lipid levels and change in lipids, were also studied. Patient- 
specific hanges were derived using the mean of the changes in 
diameter of the lesions in each patient. 
Resu l ts  
Patients. The final study group consisted of the 59 patients 
who underwent follow-up cardiac catheterization (55 men, 4 
women; 31 patients in the fish oil group, 28 in the control 
group) (Table 1). Twenty-one randomized patients did not 
complete the protocol (10 in the fish oil, 11 in the control 
group). Reasons for not completing the study were death (one 
in the control group); refusal to undergo the second cardiac 
catheterization (three in the fish oil group, nine in the control 
group); development of medical conditions precluding partic- 
ipation (three in the fish oil group, one in the control group); 
intolerance to the capsules (three in the fish oil group); and a 
missing initial angiography film (one in the fish oil group). 
There were no significant differences in the baseline char- 
acteristics of the patients between the two treatment groups 
(Tables 1 and 2). Dietary saturated fat comprised 8 _+ 2% 
(mean + SD) of energy intake in both groups at baseline and 
during follow-up. Dietary cholesterol intake, -200  _ 
90 mg/day at baseline, decreased in the fish oil group by 28 mg 
compared with an increase in the control group of 22 mg (p = 
0.04). Both groups gained a mean of 2 kg body weight during 
the trial (p < 0.005). Adherence, estimated by pill counts, 
averaged 80% in the fish oil group and 90% in the control 
group. Medication use was similar among the groups at 
baseline except for oral hypoglycemic drugs (Table 1), and 
there were no significant changes in medication use during the 
trial in either group. 
Plasma lipoprotein changes. As a group, the patients had 
average levels at baseline, and there were no significant 
differences between the fish oil and control groups (Table 2). 
Plasma triglyceride levels decreased by 30% in the fish oil 
group compared with those in the control group (p = 0.007). 
The decrease in triglyceride levels in the fish oil group was 
established by 12 weeks and remained stable throughout the 
follow-up. There were no significant differences between the 
groups in changes in plasma total, LDL or HDL cholesterol r 
apolipoprotein B or lipoprotein Lp(a) levels. Hypocholester- 
olemic drug therapy for a total cholesterol level >250 mg/dl 
(6.43 mmol/liter) was required for four patients in the fish oil 
group and none in the control group. The medications used 
were cholestyramine (4 to 8 g/day) in three patients and 
cholestyramine (8 to 16 g) with nicotinic acid (2 g) in one 
patient. 
Adipose tissue fatty acids. At the end of the trial, adipose 
tissue in the fish oil group was significantly enriched in the n-3 
polyunsaturated fatty acids of marine origin that were con- 
tained in the fish oil (p < 0.0001) (Table 3). In contrast, the 
control group that received olive oil had a significantly higher 
content of oleic acid (p = 0.0009), the major fatty acid in olive 
oil, and higher levels of palmitic acid (p = 0.05), the major 
Table 2. Body Weight and Plasma Lipid Levels at Baseline and During Fish Oil or Control Supplementation 
Fish Oil Group (n = 31) Control Group (n = 28) 
Baseline Follow-Up Difference Baseline Follow-Up Difference 
Body weight (kg) 80 + 14 82 ± 14 2 _+ 3* 79 -+ 15 80 -+ 15 2 _+ 3* 
Systolic BP (ram Hg) 126 _+ 29 129 + 16 3 _+ 29 133 + 19 137 _+ 29 5 ± 25 
Diastolic BP (mm Hg) 76 _+ 16 77 ± 7 1 _+ 18 77 -+ 7.6 77 + 7 0 ± 8 
Cholesterol (mg/dl) 189 _+ 33 194 _+ 37 5 + 17 184 _+ 28 193 _+ 24 9 ± 20t 
HDL-C (mg/dl) 41 ± 9 42 _+ 1t 1 _+ 6 40 ± 12 42 _+ 13 3 _+ 7 
LDL-C (mg/dl) 122 ± 29 132 _+ 30 10 _+ 17" 117 ± 27 122 + 24 6 + 17 
Triglycerides (mg/dl) 128 _+ 67 101 +_ 50 -28 + 53* 137 _+ 73 143 _+ 67 6 _+ 35~ 
Apolipoprotein B (mg/dl) 80 ± 13 86 ± 15 6 _+ 6* 74 ± 16 79 _+ 13 5 _+ 9* 
Lipoprotein Lp(a) (mg/dl) 8.2 _+ 4.4 9.7 _+ 5.1 1.2 ± 2.8t 6.4 _+ 3.6 5.7 ± 3.9 -1.1 ± 7.2 
*p < 0.01, tP < 0.05 for within-group changes. Sp < 0.01 for between-group changes. All differences between baseline values were not significant (p> 0.1). Data 
presented are mean value _+ SD, except those for lipoprotein Lp(a), which are geometric mean values. BP = blood pressure; HDL-C (LDL-C) high (low) density 
llpoprotein cholesterol. 
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Table 3. Adipose Tissue Fatty Acid Levels (mean _+ SD) After 2.4 Years of Fish Oil or 
Control Supplementation 
Fish Oil Control 
Group Group 
Acid (n = 29) (n = 28) p Value 
Lauric 0.74 ± 0.57 0.86 ± 0.43 0.4 
Palmitic 12.4 ± 3.7 14.1 _+ 2.5 0.048 
Stearic 3.37 -+ 0.85 3.0 _+ 0.9 0.16 
Oleic 37.3 ± 6.6 42.3 ÷ 3.9 0.0009 
Linoleic 18.2 ± 4.7 18.7 ± 3.7 0.7 
Arachidonie 0.60 ± 0.28 0.89 _+ 0.37 0.001 
EPA (n-3) 0.91 ± 0.53 0.20 ± 0.31 < 0.0001 
DPA (n-3) 0.62 ± 0.25 0.25 _+ 0.15 < 0.0001 
DHA (n-3) 0.84 _+ 0.41 0.31 _+ 0.23 < 0.0001 
EPA+DPA+DHA 2.37 _+ 1.14 0.76 ± 0.66 < 0.0001 
Two patients refused the fat biopsy. DHA - docosahexaenoic acid; DPA = docosapentaenoic acid; EPA = 
eicosapentaenoic acid. 
tissue saturated fatty acid. Arachidonic acid was lower in the 
fish oil group than in the control group (p = 0.001). 
Coronary artery lesions. The principal analysis consists of 
179 lesions in 31 patients in the active group (5.8 lesions/ 
patient) and 126 lesions in 28 patients in the control group (4.5 
lesions/patient) (Table 4, Fig. 1). The difference in number of 
lesions is mainly accounted for by a greater number of 
bypassed vessels in the fish oil group, by chance. The adjusted 
changes were -0.104 and -0.138 mm in minimal diameter 
(p = 0.6) and +2.4% and +2.6% in percent diameter narrow- 
ing (p = 0.8) in the fish oil and control groups, respectively, 
indicating slight worsening in both groups (Table 4, Fig. 1). 
The adjusted ifferences between the groups were +0.03 mm 
(95% confidence interval [CI] -0.10 to 0.17 ram) and -0.2% 
(95% CI -2.6 to 2.1%). These confidence intervals indicate 
that the trial excludes improvement by fish oil treatment of 
>0.17 mm, or >2.6% stenosis. Lesions in unbypassed vessels 
showed less change in minimal diameter than lesions that were 
in bypassed circulation (p < 0.0001), but there were no 
significant differences between the treatment groups. In con- 
trast, the diameter of normal vessel segments increased in the 
fish oil group but not in the control group (p = 0.03 between 
groups for minimal diameter; p = 0.07 for average diameter). 
Additional analyses of lesion change. Patient-specific anal- 
ysis of the changes in coronary lesions revealed no significant 
differences between the groups; for all lesions, mean change 
was -0.12 (SD 0.29) and -0.11 (SD 0.27) in the fish oil and 
control groups, respectively (p = 0.9), and for unbypassed 
lesions the changes were -0.10 (SD 0.29) and -0.11 (SD 0.34) 
(p = 0.9). For a categoric analysis, lesions were classified as 
progressing or regressing if the changes were _>7.8% in percent 
stenosis as previously determined (34). The majority of the 
lesions showed no change (Table 5), and there were no 
significant differences between the groups. Restricting the 
Table 4. Effect of Fish Oil on Coronary Artery Disease: Lesion-Specific Analysis 
Fish Oil Group Control Group 
No. of Adjusted No. of Adjusted Fish Oil - 
Lesions Pre Post Change Lesions Pre Post Change Control 
All abnormal segments 
Min diam (mm) 179 1.74 ± 0.82 1.62 _+ 0.86 -0.104 _+ 0.05 126 1.57 ± 0.71 1.46 + 0.67 -0.t38 ± 0.04* 0.03 (0.10-0.17) 
Stenosis (%) 46.5 _+ 14.2 49.4 _+ 12.5 2.4 ± 0.7* 48.7 _+ 13.7 50.7 +_ 12.2 2.6 ± 0.8* -0.2 (-2.6-2.1) 
Unbypassed abnormal segments 
Min diam (mm) 96 1.85 ± 0.85 1.82 _+ 0.94 -0.06 + 0.07 86 1.64 _+ 0.71 1.55 ± 0.70 -0.10 ± 0.04 0.04 (-0.14-0.23) 
Stenosis (%) 43.8 _+ 13.5 46.9 ± 11.7 2.9 ± 1.3t 46.7 -+ 12.8 49.2 ± 12.0 3.2 ± 1.1t -0.3 (-3.8-3.2) 
Bypassed abnormal segments 
Min diam (mm) 83 1.61 +_ 0.76 1.39 ± 0.70 -0.23 ± 0.06* 40 1.43 _+ 0.70 1.28_+ 0.54 -0.23 ± 0.06* 0.00 (-0.16-0.17) 
Stenosis (%) 49.7 ± 14.3 52.4 ± 12.8 2.3 + 1.1~ 53.1 ± 14.5 53.8 + 12.3 1.7 _+ 1.4 0.6 (3.0-4.2) 
Unbypassed normal segments 
Min diam (ram) 41 2.24 ± 0.96 2.38 ± 0.98 0.15 ± 0.07? 51 2.40 _+ 0.92 2.33 + 0.90 -0.05 ± 0.05 0.20 (0.01-0.39) 
(p = 0.03) 
Av diam (mm) 2.73 _+ 0.94 2.90 _+ 0.97 0.17 ± 0.07t 2.98 +_ 0.93 2.97 + 0.98 0.01 ± 0.07 0.19 (-0.03-0.40) 
*p < 0.01, tp < 0.05 for within-group changes. Adjusted changes were computed by multiple regression analysis with adjustment for the intraclass correlation, 
differences in pretreatment value (Pre) and proportion of bypassed lesions. Data presented are mean values -+ SD (for pretreatment and posttreatment [Post] values) 
or ±SE (for adjusted change). Av (Min) diam = average (minimal) diameter; Fish Oil - Control = difference between adjusted changes (95% confidence intervals). 
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Figure 1. Changes in coronary ar- 
tery lesions before and after 2.4 
years of treatment with fish oil. The 
between-group differences are 
shown with 95% confidence inter- 
vals (vertical lines). Changes in 
minimal coronary artery diameter 
and percent stenosis n the active 
treatment and control groups were 
adjusted for the effects of differ- 
ences in pretreatment values, for 
differences in the proportion ofle- 
sions that were in a bypassed circu- 
lation and for the intraclass corre- 
lation of the changes in lesions 
within a patient. Change = post- 
treatment minus pretreatment. 
categoric analysis to unbypassed lesions produced similar 
results to the full group. One unbypassed vessel became 
occluded in the fish oil group compared with three vessels in 
three patients in the control group. 
Subgroup analyses did not demonstrate any significant 
effect of fish oil in patients according to baseline lipid levels, 
change in lipid levels, baseline coronary lesion diameter or 
adipose tissue n-3 fatty acid levels. 
Clinical coronary disease events are counted for all ran- 
domized patients up to the time of repeat catheterization r 
for 2.4 years in the dropouts. In the fish oil group, there were 
eight events in seven patients (one nonfatal myocardial infarc- 
tion, one stroke, three coronary angioplasties, three hospital 
admissions for unstable angina). In the control group, there 
were 11 events in seven patients (1 coronary death, 2 nonfatal 
myocardial infarctions, 1 hospital admission for congestive 
heart failure, 3 coronary angioplasties, 4 hospital admissions 
for unstable angina). No patient had coronary bypass urgery 
after randomization. 
Discuss ion  
The present study found no evidence that the progression 
of coronary atherosclerosis over a 2.4-year period, as measured 
by change in lumen diameter, isaffected by fish oil supplemen- 
tation. The patients were proved to be compliant by the 
findings of a sustained ecrease inplasma triglyceride l vels in 
the fish oil group and the substantially higher n-3 fatty acid 
levels in adipose tissue biopsy samples. The equilibration time 
for dietary and adipose tissue fatty acid is -2  years (41). We 
expect hat the n-3 fatty acids enriched the patients' coronary 
lesions, as found in a previous pathologic study (42). 
Limitations of the study. The confidence intervals of the 
differences between the groups exclude beneficial effects of 
>0.17 mm in minimal coronary diameter or >2.6% stenosis. 
This finding indicates that if fish oil were to have had a 
favorable effect of magnitude similar to that reported with 
hypocholesterolemic drug therapy or with nonpharmacologic 
therapy (35,43-46), then such a difference would have been 
detectable in the present study. This sensitivity is the result of 
there being 305 lesions available for analysis, the precision of 
the angiographic measurements and the highly powered statis- 
tical analysis technique. However, it is possible that fish oil 
could produce very small improvement in coronary diameter, 
perhaps 0.04 mm as in a recent rial of lovastatin (47), that 
would not have been detected in our trial. Our trial experi- 
enced a dropout rate of 26% compared with 10% to 26% in 
previous trials of similar duration (35,38,44,45,47). The sever- 
Table 5. Effect of Fish Oil on Progression, Regression, New Lesions and Total Occlusions 
Fish Oil Group Control Group 
No. (%) of No. (%) No. (%) of No. (%) of 
Patients of Lesions Patients Lesions 
(n = 31) (n = 179) (n = 28) (n = 126) 
Progression* 11 (35%) 52 (29%) 12 (43%) 24 (19%) 
Regression 4 (13%) 23 (13%) 7 (25%) 20 (16%) 
Mixed 14 (45%) -- 6 (21%) - -  
Total occlusions 6 (19%) 12 (7%) 6 (21%) 9 (7%) 
No changes 2 (6%) 101 (51%) 3 (11%) 78 (62%) 
New lesions 2 (6%) 3 (2%) 4 (14%) 4 (3%) 
*Total occlusions not included. 
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ity of coronary disease in the present trial is similar to or worse 
than that of previous tudies (35,38,43-47). Previous studies 
conflict as to whether mild or severe lesions are benefited by 
therapy (45,47). Finally, although the duration of the treat- 
ment, 28 months, is similar to (35,38,45,47) or longer than 
(43,46) previous regression trials, we cannot exclude the 
possibility that fish oil could produce benefit that is too gradual 
to be detected or that is preceded by a latent period of _>2 years. 
Potential biologic causes of lack of benefit. 1) The olive oil 
that the control group received for a placebo could have been 
beneficial, for example, by improving serum lipids (48). This 
seems to be unlikely, because no lipid-lowering effect was 
evident in our patients in the control group, and the control 
group showed progression of disease at a comparable extent to 
that in the control groups in other arteriographic trials. 2) Fish 
oil could have a proatherosclerotic action because the highly 
unsaturated fatty acids appear to increase the susceptibility of 
LDL for oxidation (14,15), an event hat enhances the athero- 
genicity of LDL in cultured cells. However, the net effect of 
fish oil on LDL oxidation in vivo is not certain because 
laboratory studies found potentially beneficial counterbalanc- 
ing actions of fish oil, including protection from atherogenic 
effects of oxidized LDL (49), diminished production of super- 
oxide by monocytes (50), prevention of lipid peroxidation by 
platelets (51) and stimulation of alpha-tocopherol incorpora- 
tion into cell membranes (52). 
We found that the diameter of normal coronary arteries 
increased in the fish oil but not in the control group, a finding 
of borderline significance (p = 0.07 for average diameter; p = 
0.04 for minimal diameter). Because the change in normal 
arteries was not a primary end point, this could be caused by 
chance in view of multiple statistical comparisons. However, it 
is possible that fish oil promoted vasodilation in these arteries 
or improved their endothelial function (3-6). 
Patients with normal plasma lipid levels were studied 
because hypocholesterolemic drug treatment has been recom- 
mended for hyperlipidemic patients. In this normolipidemic 
group, the possibility that coronary atherosclerosis might be 
less dependent on plasma cholesterol levels made fish oil an 
attractive intervention because the mechanism ofaction could 
be independent of the effects on plasma lipid levels 
(2,3,16,21,22). In our patients, the mean plasma cholesterol 
level, 187 mg/dl (4.83 mmol/liter), is by far the lowest of any 
human atherosclerosis regression trial. Despite our patients' 
low cholesterol levels, the coronary lesions in the fish oil and 
control groups progressed ata similar ate as in hyperlipidemic 
patients in certain previous tudies. In both groups, the pro- 
gression of lesions was not correlated with plasma lipid levels, 
indicating that in this population, nonlipid risk factors may 
regulate the atherosclerotic process. 
Conclusions. Epidemiologic and intervention studies do 
not reveal a clear picture of the effects of fish oil on coronary 
atherosclerosis. Arctic peoples consume marine oils in fish and 
sea mammals and have low rates of coronary heart disease (1). 
Certain observational studies in industrialized countries have 
found a protective association of fish intake on the develop- 
ment of coronary heart disease (53-55), but other studies have 
not (56-59). However, fish intake is much lower in these 
countries than in the arctic. Restenosis after coronary angio- 
plasty is not convincingly benefited espite multiple studies 
(28,29,60). The most compelling evidence in favor of fish is a 
clinical trial of patients who had coronary heart disease (2). 
Patients were asked to ingest wo portions per week of fatty 
fish, which supplied -0.5 mg of n-3 fatty acids daily, one- 
twelfth of the dose in our trial. Death and recurrent nonfatal 
coronary heart disease were lowered early in the 5-year 
follow-up period in the fish group compared with that in the 
control group. It is possible that fish oil could prevent coronary 
events by retarding thrombosis or improving endothelial func- 
tion that leaves coronary stenosis unchanged orby preventing 
fatal ventricular arrhythmias (61). Alternatively, the relatively 
low quantity of n-3 fatty acids consumed in the previous trial 
(2) raises a question about the effect of fish oil itself and 
supports the possibility that other constituents of the fish are 
cardioprotective. In view of these uncertainties, a definitive 
assessment of the effect of fish oil on coronary heart disease 
requires a sufficient number of patients to determine whether 
myocardial infarction and death rates are reduced. 
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